USA flag logo/image

An Official Website of the United States Government

Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95728
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI084350
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
BIOPROTECTION SYSTEMS CORP.
2901 S LOOP DR STE 3360 Ames, IA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses
Agency: HHS
Contract: 1R43AI084350-01A1
Award Amount: $599,895.00
 

Abstract:

DESCRIPTION (provided by applicant): Indigenous population, travelers and troops present in Africa and South America are clearly at risk of exposure to several arenaviruses. Several human pathogenic arenaviruses, e.g., Lassa and Junin viruses, are listed o n the NIAID's Priority Pathogens and CDC's Bioterrorism Agents Lists and can cause a deadly hemorrhagic fever. No effective and safe vaccine is currently available to combat these diseases. In addition, effective arenavirus vaccines are needed for the Stra tegic National Stockpile in preparation for a potential bioterror attack in the United States. A commonly used, safe vaccine platform based on the Yellow fever (YF) vaccine 17D will be exploited to generate a protective vaccine against arenaviral infection s. The live-attenuated YF-17D virus vaccine strain has been used for human immunization since 1936. More than 500 million people have been vaccinated with YF-17D over the past 70 years, and the vaccine has a truly remarkable record of safety and efficacy. A single subcutaneous immunization with YF-17D elicits long-lasting protective antibodies and cellular immune responses. We will use this vaccine platform to generate multivalent arenavirus vaccines protecting against YFV and different arenaviruses. This new vaccine approach represents an important upgrade/replacement for the standard YF-17D vaccine that will provide immunity to both YF and important arenaviruses. Besides the overall known safety of the vaccine platform, the published proof of concept for the use of this platform to protect against a deadly arenavirus, and the advantage of targeting different viral diseases in a similar geographical location (e.g., YF and Lassa fever - Lassa virus in West Africa; YF and Argentine hemorrhagic fever- Junmn v irus in South America) makes this approach ideal as a prophylactic treatment for protecting indogenous populations, travelers and warfighters. Importantly, the multivalent YF-17D vaccine platform is readily adaptable for the generation of immunity to othe r viral families, such as bunyaviruses (Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus) and henipaviruses (Nipah virus, Hendra virus), all of which present (i) a real threat to the indigenous populations and travelers in locations including Africa, Middle East and Southeast Asia, and (ii) a bioterror threat to the United States and its allies. PUBLIC HEALTH RELEVANCE: Yellow fever viruses and arenaviruses (e.g., Junin, Lassa) that cause hemorrhagic fever (HF) are serious health concer ns - as emerging diseases as well as bioterror threats. We will use the safe and approved Yellow Fever 17D vaccine as a platform to develop a multivalent Yellow fever-arenavirus vaccine. This new multivalent vaccine will simultaneously protect against seve ral hemorrhagic fever-causing pathogens.

Principal Investigator:

Ramon Flick
5152963944
RFLICK@BPSYS.NET

Business Contact:

Carl Langren
clangren@bpsys.net
Small Business Information at Submission:

BIOPROTECTION SYSTEMS CORPORATION
BIOPROTECTION SYSTEMS CORPORATION 2901 S LOOP DR, STE 3360 AMES, IA -

EIN/Tax ID: 120284463
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No